Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-16 EDT			5-day change	1st Jan Change
147.4 ^USD	-0.01%		+2.90%	+11.91%

07-09	RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating	MT
07-03	ANALYST RECOMMENDATIONS : Alphabet, Nike, Nvidia, Tesla, Starbucks...

Neurocrine Biosciences, Inc. Provides Preliminary Sales Results for the Fourth Quarter and Full-Year 2020

January 08, 2021 at 07:32 am

Neurocrine Biosciences, Inc. provided preliminary sales results for the fourth quarter and full-year 2020. the Company expects INGREZZA net product sales for the three months and full-year ended December 31, 2020 to be approximately $240 million and $993 million respectively.

Latest news about Neurocrine Biosciences, Inc.

RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating	07-09	MT
ANALYST RECOMMENDATIONS : Alphabet, Nike, Nvidia, Tesla, Starbucks...	07-03
Neurocrine Biosciences Insider Sold Shares Worth $1,401,864, According to a Recent SEC Filing	07-03	MT
Neurocrine Biosciences Says US FDA Accepts NDAs With Priority Review for Adrenal Gland Disease Drug	07-01	MT
Neurocrine Biosciences Gets FDA Priority Review for Crinecerfont	07-01	DJ
Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH	07-01	CI
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell 1000 Defensive Index	06-30	CI
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell 1000 Growth-Defensive Index	06-30	CI
Transcript : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-13-2024 10:40 AM	06-13
Transcript : Neurocrine Biosciences, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 02:30 PM	06-05
Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	06-03	CI
Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	06-03	CI
Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing	05-31	MT
Neurocrine Biosciences Says CEO Kevin Gorman Retiring	05-28	MT
Neurocrine founder-CEO Gorman to retire in October	05-28	RE
Neurocrine CEO set to retire	05-28	RE
Neurocrine Biosciences, Inc. Announces Dr. Kyle Gano as Director, Effective October 11, 2024	05-28	CI
Neurocrine Biosciences Announces CEO Changes	05-28	CI
UBS Raises Price Target on Neurocrine Biosciences to $193 From $174, Maintains Buy Rating	05-28	MT
Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing	05-21	MT
Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis	05-21	CI
Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing	05-16	MT
Transcript : Neurocrine Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM	05-14
Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024	05-14	CI
Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024	05-09	CI

Chart Neurocrine Biosciences, Inc.

Duration

Period

More charts

Company Profile

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntingtonâs disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Sector

Biotechnology & Medical Research

Calendar

2024-08-01 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Neurocrine Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

147.5 USD

Average target price

160.9 USD

Spread / Average Target

+9.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B
INSMED INCORPORATED	+151.63%	12.49B

Bio Therapeutic Drugs